Literature DB >> 7911394

Reversal of multidrug resistance by RU 486.

D J Gruol1, M C Zee, J Trotter, S Bourgeois.   

Abstract

P-Glycoproteins represent a family of drug efflux proteins that convey multidrug resistance to cells in which they are expressed. This phenomenon can lower the efficacy of drugs used in chemotherapy. The steroid progesterone has been shown to bind P-glycoproteins and inhibit their drug efflux. We report that the antiprogestin RU 486 can reverse multidrug resistance in cells overexpressing the mouse mdr1 gene. Using flow cytometry to measure inhibition of P-glycoprotein-dependent efflux of rhodamine 123, RU 486 was found to be considerably more effective than progesterone and one-half as effective as verapamil. The results suggest a valuable new use for RU 486.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7911394

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders.

Authors:  Gloria Lee; Reina Bendayan
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

2.  In vitro effects of RU486 on proliferation and differentiation capabilities of human bone marrow mesenchymal stromal cells.

Authors:  Yang Yu; Na Wei; Clark Stanford; Thomas Schmidt; Liu Hong
Journal:  Steroids       Date:  2011-11-07       Impact factor: 2.668

Review 3.  Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics.

Authors:  Magdalena Markowicz-Piasecka; Agata Markiewicz; Patrycja Darłak; Joanna Sikora; Santosh Kumar Adla; Sreelatha Bagina; Kristiina M Huttunen
Journal:  Neurotherapeutics       Date:  2022-04-07       Impact factor: 6.088

4.  Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein.

Authors:  G Conseil; H Baubichon-Cortay; G Dayan; J M Jault; D Barron; A Di Pietro
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

Review 5.  Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use.

Authors:  G R Jang; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1997-12

6.  Reversal of multidrug resistance in drug-resistant human gastric cancer cell line SGC7901/VCR by antiprogestin drug mifepristone.

Authors:  Da-Qiang Li; Zhi-Biao Wang; Jin Bai; Jie Zhao; Yuan Wang; Kai Hu; Yong-Hong Du
Journal:  World J Gastroenterol       Date:  2004-06-15       Impact factor: 5.742

Review 7.  Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

Authors:  Shufeng Zhou; Sui Yung Chan; Boon Cher Goh; Eli Chan; Wei Duan; Min Huang; Howard L McLeod
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

8.  ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal.

Authors:  Cheol-Hee Choi
Journal:  Cancer Cell Int       Date:  2005-10-04       Impact factor: 5.722

9.  Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.

Authors:  Jan Kroon; Martin Puhr; Jeroen T Buijs; Geertje van der Horst; Daniëlle M Hemmer; Koen A Marijt; Ming S Hwang; Motasim Masood; Stefan Grimm; Gert Storm; Josbert M Metselaar; Onno C Meijer; Zoran Culig; Gabri van der Pluijm
Journal:  Endocr Relat Cancer       Date:  2015-10-19       Impact factor: 5.678

10.  The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer.

Authors:  Gonzalo Sequeira; Silvia I Vanzulli; Paola Rojas; Caroline Lamb; Lucas Colombo; Maria May; Alfredo Molinolo; Claudia Lanari
Journal:  Oncotarget       Date:  2014-05-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.